Six notes:
1. For the third quarter of 2021, selling, general and administrative expenses were about $2.6 million, compared to about $1.9 million for the third quarter of 2020.
2. Net loss was $2 million, or $.06 per share, compared to $2.1 million during the same period last year.
3. Net product sales were about $930,000, compared to $237,000 in the second quarter of this year.
4. Research and development expenses totaled about $100,000 for the third quarter of this year, compared to $200,000 for the same period last year.
5. As of Sept. 30, Evoke’s cash and cash equivalents were about $11.1 million
6. The company had 84 new prescribers added in the third quarter of this year.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
